Titlebook: Innovations for Next-Generation Antibody-Drug Conjugates; Marc Damelin Book 2018 Springer International Publishing AG, part of Springer Na

沒血色

建筑師

Inkling

carotenoids

pus840

恃強凌弱

Bispecific and Biparatopic Antibody Drug Conjugates,in the early 1900’s the concept of a “magic bullet”, an ideal therapeutic that would specifically target a disease-causing agent without causing harm to the body. This concept still underpins the overarching goal of biopharmaceutical development today: to produce drugs that have a broad therapeutic

irreparable

xanthelasma

Antibody-Drug Conjugates: Targeting the Tumor Microenvironment,th the aim to increase anti-cancer activity and spare normal tissues from undesired toxicity. Until recently, most ADC development activities have focused on the use of monoclonal antibodies, capable of selective binding and internalization into the target tumor cells. However, in principle, it woul

compassion

Next Horizons: ADCs Beyond Oncology,eyond oncology. The key variables for oncology ADCs in terms of the targeted cell type, targeting strategy, and payload are often clearer while the corresponding elements for non-oncology indications are more complex. Challenges in designing such non-oncology ADCs include selecting the targeting cel

arboretum